Expanding the armamentarium against respiratory viral infections: DAS181

Journal of Infectious Diseases

Volumn 206, Issue 12, 2012, Pages 1806-1808

  Ison, Michael G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; DAS 181; OSELTAMIVIR; PARACETAMOL; PLACEBO; RIMANTADINE; SIALIDASE; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CLINICAL ASSESSMENT; GENE MUTATION; HUMAN; HYPERTRANSAMINASEMIA; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MORBIDITY; MORTALITY; NONHUMAN; NOTE; PANDEMIC; PARAINFLUENZA VIRUS; PARAINFLUENZA VIRUS INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SINGLE DRUG DOSE; VIRAL RESPIRATORY TRACT INFECTION;

ANTIVIRAL AGENTS; FEMALE; HUMANS; INFLUENZA, HUMAN; MALE; RECOMBINANT FUSION PROTEINS;

EID: 84870228102     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis623     Document Type: Note

References (28)

1. Lee N, Ison MG. "Late" treatment with neuraminidase inhibitors for severely ill influenza patients: Better late than never? Clinical Infectious Diseases 2012 [epub ahead of print].
2. Duncan IG, Taitel MS, Zhang J, Kirkham HS. Planning influenza vaccination programs: A cost benefit model. Cost Effectiveness and Resource Allocation 2012; 10:10.
3. Bautista E, Chotpitayasunondh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A(H1N1) virus infection. The New England Journal of Medicine 2010; 362: 1708-19.
4. Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: A modelling study. The Lancet Infectious Diseases 2012; 12:687-95.
5. Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev 2006: CD001169.
6. Moscona A. Neuraminidase inhibitors for influenza. The New England Journal of Medicine 2005; 353:1363-73. (Pubitemid 41362704)
7. Lee N, Ison MG. Diagnosis, management and outcomes of adults hospitalized with influenza. Antiviral Therapy 2012; 17:143-57.
8. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. The Journal of Infectious Diseases 2007; 196:249-57. (Pubitemid 47047464)
9. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report Recommendations and Reports 2011; 60:1-24.
10. Fry AM, Gubareva LV. Understanding influenza virus resistance to antiviral agents; early warning signs for wider community circulation. The Journal of Infectious Diseases 2012; 206:145-7.
11. Boltz DA, Aldridge JR Jr, Webster RG, Govorkova EA. Drugs in development for influenza. Drugs 2010; 70:1349-62.
12. Moscona A, Porotto M, Palmer S, et al. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo. The Journal of Infectious Diseases 2010; 202:234-41.
13. Triana-Baltzer GB, Gubareva LV, Klimov AI, et al. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PloS One 2009; 4:e7838.
14. Triana-Baltzer GB, Gubareva LV, Nicholls JM, et al. Novel pandemic influenza A (H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PloS One 2009; 4:e7788.
15. Chan RW, Chan MC, Wong AC, et al. DAS181 inhibits H5N1 influenza virus infection of human lung tissues. Antimicrobial Agents and Chemotherapy 2009; 53:3935-41.
16. Zhang H. DAS181 and H5N1 virus infection. The Journal of Infectious Diseases 2009; 199:1250, author reply 1250-1.
17. Belser JA, Lu X, Szretter KJ, et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. The Journal of Infectious Diseases 2007; 196:1493-9. (Pubitemid 351411986)
18. Malakhov MP, Aschenbrenner LM, Smee DF, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrobial Agents and Chemotherapy 2006; 50:1470-9.
19. Triana-Baltzer GB, Sanders RL, Hedlund M, et al. Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181. The Journal of Antimicrobial Chemotherapy 2011; 66:15-28.
20. Hedlund M, Aschenbrenner LM, Jensen K, Larson JL, Fang F. Sialidase-based antiinfluenza virus therapy protects against secondary pneumococcal infection. The Journal of Infectious Diseases 2010; 201:1007-15.
21. Moss RB, Hansen C, Sanders RL, Hawley S, Li T, Steigbigel RT. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. The Journal of Infectious Diseases 2012. [in this issue].
22. Ison MG, de Jong MD, Gilligan KJ, et al. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. The Journal of Infectious Diseases 2010; 201:1654-62.
23. Vu DL, Bridevaux PO, Aubert JD, Soccal PMKaiser L. Respiratory viruses in lung transplant recipients: A critical review and pooled analysis of clinical studies. American Journal of Transplantation 2011; 11:1071-8.
24. Renaud C, Englund JA. Antiviral therapy of respiratory viruses in haematopoietic stem cell transplant recipients. Antiviral Therapy 2012; 17:175-91.
25. Chien JW, Martin PJ, Gooley TA, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. American Journal of Respiratory and Critical Care Medicine 2003; 168: 208-14. (Pubitemid 36920975)
26. Erard V, Chien JW, Kim HW, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: The role of community respiratory viruses. The Journal of Infectious Diseases 2006; 193:1619-25. (Pubitemid 43839464)
27. Chen YB, Driscoll JP, McAfee SL, et al. Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation. Clinical Infectious Diseases 2011; 53:e77-80.
28. Guzman-Suarez BB, Buckley MW, Gilmore ET, et al. Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients. Transplant Infectious Disease 2012; 14:427-33.